Chemotherapy Administration Guidelines for Metastatic Cancer

Standard Treatment Duration and Frequency

The European Society for Medical Oncology recommends that adult patients with metastatic cancer and good performance status receive IV chemotherapy every 2-3 weeks for a total of 4-6 cycles, with a maximum of 6 cycles recommended for most solid tumors 1, 2, 3
Most patients should receive 4 cycles of chemotherapy as the recommended standard, with a maximum of 6 cycles, as suggested by the European Society for Medical Oncology 1, 3
Cytotoxic combinations should be administered for no more than 6 cycles, according to the American Society of Clinical Oncology 2
For advanced-stage disease, 6-8 cycles may be appropriate in select cases, such as ovarian cancer, as recommended by the National Comprehensive Cancer Network 4

The European Society for Medical Oncology recommends that platinum-based combination chemotherapy be administered every 3 weeks for patients with good performance status 1, 3
Chemotherapy should be initiated while the patient maintains good performance status, as suggested by the European Society for Medical Oncology 1, 3
For patients with moderate performance status, single-agent chemotherapy with gemcitabine, vinorelbine, or taxanes represents an option, according to the European Society for Medical Oncology 1, 3
Platinum-based combinations may also be considered as an alternative for patients with moderate performance status, as recommended by the European Society for Medical Oncology 1, 3

Patients should be reevaluated after 2-3 cycles of chemotherapy, and treatment should be continued for 2 more cycles in patients whose disease responds or remains stable, as suggested by the National Comprehensive Cancer Network 6
If no response is noted after 2 cycles or significant morbidities occur, therapy should be changed, according to the National Comprehensive Cancer Network 6
Evidence does not support continuation of cytotoxic chemotherapy until disease progression for patients with stable disease or response to first-line therapy, as recommended by the American Society of Clinical Oncology 2

For non-small cell lung cancer, the standard frequency is every 3 weeks for 4-6 cycles maximum, as recommended by the European Society for Medical Oncology 1, 3
For bladder cancer, gemcitabine/cisplatin should be administered every 3-4 weeks for a maximum of 6 cycles, according to the National Comprehensive Cancer Network 6
For ovarian cancer, 6-8 cycles are recommended for advanced-stage disease, as suggested by the National Comprehensive Cancer Network 4